Sonoma Pharmaceuticals Q4 EPS $(0.07) Up From $(0.31) YoY, Sales $3.44M Miss $3.98M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported Q4 EPS of $(0.07), a significant improvement from $(0.31) YoY, but missed sales estimates with $3.44M against the expected $3.98M.
June 17, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sonoma Pharmaceuticals reported a significant improvement in EPS, reducing losses from $(0.31) to $(0.07) YoY. However, the company missed sales estimates, reporting $3.44M against the expected $3.98M.
While the improvement in EPS is a positive sign, the miss on sales estimates could offset the positive sentiment. Investors may have mixed reactions, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100